A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval
People with Lynch syndrome have a very high lifetime cancer risk from a predictable set of mutations. Vaccinate them against those shared mutations before cancer appears.
Mismatch repair deficiency produces recurrent frameshift neoantigens shared across Lynch-associated tumours, and pilot vaccines have shown immunogenicity in carriers and in mice reduced tumour incidence. The proposal is to take a multi-epitope frameshift vaccine (mRNA or viral vector, possibly with a checkpoint-sparing adjuvant) into a randomised prevention trial in carriers with a surrogate endpoint of adenoma and early-cancer incidence at colonoscopy, positioning it as the first preventive cancer vaccine registration for a hereditary syndrome.
- Inherited risk is mostly unidentified · Most people who carry a high-risk cancer gene do not know it until they or a relative gets cancer.
- Prevention we already have is not deployed · Around four in ten cancers are preventable with tools we already own: vaccines, tobacco control, weight, alcohol, sun and infection control.
Pages like this
not linked directly; found by shared links- IdeaA randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers
Shares Cancer interception vaccines for high-risk carriers, First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, Off-the-shelf cancer vaccines, Neoantigen.
- CompanyNouscom
Shares Off-the-shelf cancer vaccines, Neoantigen, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Colorectal cancer.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- CompanyGritstone bio
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines, Colorectal cancer.
- IdeaGet every Lynch syndrome carrier onto the right dose of aspirin
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Prevention we already have is not deployed, Colorectal cancer.
- TermLynch syndrome
Shares First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Endometrial cancer.
- Key paperCAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years
Shares Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Inherited risk is mostly unidentified, Endometrial cancer, Prevention we already have is not deployed.
- IdeaVaccinate against the resistance mutation before it takes over
Shares Off-the-shelf cancer vaccines, Neoantigen, Personalised neoantigen (mRNA) vaccines.